A detailed history of First Manhattan CO transactions in Nektar Therapeutics stock. As of the latest transaction made, First Manhattan CO holds 500 shares of NKTR stock, worth $585. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 500 -0.0%
Holding current value
$585
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 16, 2021

BUY
$16.52 - $20.4 $8,260 - $10,200
500 New
500 $8,000
Q3 2018

Oct 15, 2018

SELL
$46.46 - $68.49 $27,876 - $41,094
-600 Closed
0 $0
Q1 2018

Apr 20, 2018

BUY
$57.4 - $108.44 $34,440 - $65,064
600 New
600 $63,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $219M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track First Manhattan CO Portfolio

Follow First Manhattan CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Manhattan CO, based on Form 13F filings with the SEC.

News

Stay updated on First Manhattan CO with notifications on news.